Neurochem/J&J’s Kiacta Action Date Extended To July 16
This article was originally published in The Pink Sheet Daily
Executive Summary
Canadian firm responded last fall to an “approvable” letter for the Amyloid A amyloidosis treatment and submitted additional information in February.
You may also be interested in...
Poor “Site Effect” Profile? Neurochem Reports Inconclusive Alzheimer’s Data For Alzhemed
Canadian firm will base Alzhemed next steps on Special Advisory Board analysis of North American trial data.
Poor “Site Effect” Profile? Neurochem Reports Inconclusive Alzheimer’s Data For Alzhemed
Canadian firm will base Alzhemed next steps on Special Advisory Board analysis of North American trial data.
Neurochem’s Alzhemed On Fast Track For Alzheimer’s Disease
Firm has August meeting scheduled with FDA to review Phase III data and discuss statistical review of current and future results.